SynthesisCurrent cancer drug targets2026
A Comprehensive Evaluation of the Effectiveness and Safety of Pembrolizumab for the Treatment of Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.
Synthesis in Current cancer drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThis comprehensive assessment and quantitative synthesis aimed to assess the effectiveness and safety profile of pembrolizumab, an antagonist of the programmed cell death protein 1 [PD-1] pathway, for individuals with metastatic colorectal carcinoma (mCRC).
methodsA comprehensive search of scholarly articles was performed using the PubMed and Web of Science [WOS] databases from January 2015 to August 2024. The scope of the search was limited to randomized controlled trials and clinical studies that reported the effectiveness of pembrolizumab in patients with metastatic colorectal cancer (mCRC), which emphasized critical indicators, such as overall survival, progression-free survival, objective response rate, and disease control rate. The research also considered secondary outcomes, including the incidence of severe adverse events and mortality rates. Data extraction was performed by two independent reviewers, who employed a standardized data collection form. The subsequent meta-analysis was performed using RevMan 5.0, a software tool for statistical analysis.
resultsSix studies with 1,634 patients were included, and of these patients, 812 were in the pembrolizumab group, and 822 were in the control group. The results of the metaanalysis indicated via the standard mean difference (SMD) that the overall survival [OS] of patients in the pembrolizumab group was significantly different from that of patients in the control group (SMD = 0.21, 95% CI (0.09, 0.32), P = 0.0005). The progression-free survival (PFS) of patients in the pembrolizumab group was slightly longer than that of patients in the control group according to the SMD, and this difference was statistically significant (SMD = 0.11, 95% CI (0.01, 0.22), P = 0.03). Compared with the objective response rate (ORR) of patients in the control group, that of patients in the pembrolizumab group was significantly higher (OR = 1.71, 95% CI (1.34, 2.17), P < 0.0001). The mortality rate in the pembrolizumab group was also significantly different from that in the control group (OR = 0.67, 95% CI (0.52, 0.87), P = 0.002).
conclusionPembrolizumab may help improve overall survival (OS) and progression-free survival (PFS) in patients with metastatic colorectal cancer, which can potentially reduce the mortality rate. More research using larger, well-designed studies is needed to further confirm these findings.
Indexed as
Identifiers
40277063What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.